US2005171048A1PendingUtilityA1

2' Modified oligonucleotides

Assignee: ISIS PHARMACEUTICALS INCPriority: Oct 24, 1989Filed: Feb 22, 2005Published: Aug 4, 2005
Est. expiryOct 24, 2009(expired)· nominal 20-yr term from priority
C07H 19/20C12N 15/113C12N 2310/321C07H 19/10C12N 2310/3517C12N 2310/3527C07H 19/06C12N 2310/3535C12N 2310/322C07H 21/00C07H 19/16C07H 19/04C12N 2310/353
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Oligomers which have substituents on the 2′ position are resistant to oligonucleases and furthermore can be derivatized to deliver reagents or drugs, to carry label, or to provide other properties.

Claims

exact text as granted — not AI-modified
1 - 63 . (canceled)  
     
     
         64 . A mixed sequence oligonucleotide having the formula:  
       
         
           
           
               
               
           
         
       
       or a salt thereof, wherein: 
 each B independently is a protected or unprotected purine or pyrimidine base in the β-anomeric configuration;  
 W 3  and W 4  are each independently H, PO 3   −2 , a protecting group, or an intermediate moiety in the formation of an internucleotide link which when reacted with the appropriate —OH results in Z;  
 n is an integer of 1-200;  
 each Z is independently is P(O)O, P(O)S or P(O)N(R) 2 ;  
 each R is independently H or alkyl (C 1-6 );  
 each A is H, OH, O—Pr wherein Pr is a protecting group, or X—Y wherein: 
 X is O, S or NH; and  
 Y is a bivalent bridging moiety, including methylene groups of the formula:  
   —(CH 2 ) nn —,  wherein nn is 1, 2, 3 or 4,    
 
 and at least one A is X—Y.

Join the waitlist — get patent alerts

Track US2005171048A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.